Research Papers:

Saikosaponin A inhibits IL-1β-induced inflammatory mediators in human osteoarthritis chondrocytes by activating LXRα

Hang Gao, Yanyan Song, Dongsong Li, Wei Feng and Jianguo Liu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:88941-88950. https://doi.org/10.18632/oncotarget.21495

Metrics: PDF 1280 views  |   HTML 2117 views  |   ?  


Hang Gao1, Yanyan Song2, Dongsong Li1, Wei Feng1 and Jianguo Liu1

1Department of Bone and Joint Surgery, The First Hospital of Jilin University, Changchun, Jilin Province, China

2Department of Nephrology, The Second Hospital of Jilin University, Changchun, Jilin Province, China

Correspondence to:

Jianguo Liu, email: [email protected]

Keywords: osteoarthritis chondrocyte, IL-1β, NF-κB, LXRα

Received: May 04, 2017     Accepted: August 26, 2017     Published: September 30, 2017


Saikosaponin a (SSa), one of the main active components of Bupleurum falcatum, has been reported to have anti-inflammatory effect. In the present study, we investigated the anti-inflammatory effect of SSa on IL-1β-stimulated human osteoarthritis chondrocytes. The cells were pretreated with SSa 12 h before IL-1β treatment. The production of PGE2 and NO were detected by ELISA and Griess method. The levels of MMP1, MMP3, and MMP13 were measured by ELISA and qRT-PCR. The expression of NF-κB and LXRα were tested by western blot analysis. The results showed that SSa inhibited IL-1β-induced PGE2 and NO production in a concentration-dependent manner. SSa also suppressed IL-1β-induced MMP1, MMP3, and MMP13 production. Furthermore, SSa significantly attenuated IL-1β-induced phosphorylation levels of NF-κB p65 and IκBα. SSa also up-regulated the expression of LXRα. The inhibition of SSa on PGE2, NO, MMP1, MMP3, and MMP13 production were reversed by LXRα siRNA or GGPP, the inhibitor of LXRα. In conclusion, our results demonstrated that SSa inhibited inflammatory responses in human chondrocytes in vitro. SSa might be a potential therapeutic drug for osteoarthritis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21495